The content on this site is intended for healthcare professionals only
Dr Tom Stinchcombe gives his thoughts on the latest developments in other therapies treatments in lung cancer from ASCO Direct Highlights 2022, which target the following mutations: MET exon 14, c-MET, BRAF, KRAS, RET, NTRK and NRG1.
Dr Stinchcombe concludes by highlighting the need for broad-based testing to detect these mutations in lung cancer patients.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
